Fennec Pharmaceuticals Inc. develops and commercializes PEDMARK®, protected by patents expiring in 2038-2039. In March 2026, it settled patent infringement litigation with Cipla, postponing generic competition until at least September 2033. Despite continued revenue growth since 2021, Fennec remains unprofitable with a net loss of $9.7 million in FY2025 and operating cash flow deficit of $12.5 million. The company’s moat relies heavily on its patent portfolio and regulatory exclusivities, but ongoing risks from patent challenges and healthcare pricing pressures persist. Monitoring future patent defenses, commercialization progress outside the U.S., and cash burn will be critical for assessing its trajectory.